Severe Asthma and Biological Therapies: Now and the Future

Recognition of phenotypic variability in pediatric asthma allows for a more personalized therapeutic approach. Knowledge of the underlying pathophysiological and molecular mechanisms (endotypes) of corresponding biomarkers and new treatments enables this strategy to progress. Biologic therapies for...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Clinical Medicine 2023, Vol.12 (18)
Main Authors: Sardon-Prado, Olaia, Diaz-Garcia, Carolina, Corcuera-Elosegui, Paula, Korta-Murua, Javier, Valverde-Molina, Jose, Sanchez-Solis, Manuel
Format: Report
Language:English
Subjects:
Analysis
Asthma in children
Biological markers
Biological products
Care and treatment
Diagnosis
Health aspects
Risk factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recognition of phenotypic variability in pediatric asthma allows for a more personalized therapeutic approach. Knowledge of the underlying pathophysiological and molecular mechanisms (endotypes) of corresponding biomarkers and new treatments enables this strategy to progress. Biologic therapies for children with severe asthma are becoming more relevant in this sense. The T2 phenotype is the most prevalent in childhood and adolescence, and non-T2 phenotypes are usually rare. This document aims to review the mechanism of action, efficacy, and potential predictive and monitoring biomarkers of biological drugs, focusing on the pediatric population. The drugs currently available are omalizumab, mepolizumab, benralizumab, dupilumab, and 1ezepelumab, with some differences in administrative approval prescription criteria between the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Previously, we described the characteristics of severe asthma in children and its diagnostic and therapeutic management.
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm12185846